Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800523 | 0.83 | IKBKB (0.47) | CCNB2CDK1CCNB1CCNB3PIK3CG | |
| SCHEMBL6795561 | 0.80 | CCNB2 (0.54) | CCNB2CDK1CCNB1CCNB3PIK3CG | |
| SCHEMBL6800610 | 0.79 | PLK1 (0.56) | PIK3CGPIK3CAPIK3CBLMNAEIF2AK2 | |
| SCHEMBL6805736 | 0.79 | CDK2 (0.61) | CDK1CCNB1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL6158104 | 0.73 | CDK2 (0.74) | CDK1EIF2AK2CDK2CDK4AURKA | |
| SCHEMBL6797232 | 0.72 | LMNA (0.57) | LMNAGAAKDM4EAURKANPC1 | |
| SCHEMBL6797526 | 0.72 | PIK3CA (0.67) | CCNB2CDK1CCNB1CCNB3PIK3CG | |
| SCHEMBL6798770 | 0.72 | ABL1 (0.63) | CCNB2CDK1CCNB1CCNB3PIK3CG | |
| SCHEMBL3779637 | 0.72 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL4313542 | 0.71 | LMNA (0.63) | CCNB2CDK1CCNB1CCNB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | claimed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | claimed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | claimed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CCNB2 44/4885CDK1 12/4885CCNB1 34/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CCNB2 44/4885CDK1 12/4885CCNB1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.